PDCD1 and acute respiratory distress syndrome: Respiratory manifestations are also reported, such as immune-related pneumonitis after the use of anti-PD1/anti-PD-L1 agents, with the most severe AE being the DADsyndrome, including diffuse damage of the alveoli, a hallmark of acute respiratory distress syndrome (ARDS).